Screener
CytomX Therapeutics CTMX Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from CytomX Therapeutics’s reported figures.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
FAQ
- What is CytomX Therapeutics's enterprise value?
- CytomX Therapeutics (CTMX) reported enterprise value of $804.87M in Q2 2026.
- How has CytomX Therapeutics's enterprise value changed year-over-year?
- CytomX Therapeutics's enterprise value increased by 172.8% year-over-year, from $294.99M to $804.87M.
- What is the long-term trend for CytomX Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), CytomX Therapeutics's enterprise value has grown at a 22.3% compound annual growth rate (CAGR), from $260.39M to $713.37M.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about CytomX Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude